Jump to Content

—

Print
Save
Email this link

Share Link

Copy this link, or click below to email it to a friend
Email this link
or copy the link directly:

https://jnccn.org/noresults?access=all&f_0=author&q_0=Judith+C.+McCaffrey
The link was not copied. Your current browser may not support copying via this button.

Link copied successfully

Search Results

You are looking at 1 - 2 of 2 items for

Author: Judith C. McCaffrey x

Refine by Access: All x

Clear All Modify Search

Full access

Anaplastic Thyroid Carcinoma, Version 2.2015

Robert I. Haddad, William M. Lydiatt, Douglas W. Ball, Naifa Lamki Busaidy, David Byrd, Glenda Callender, Paxton Dickson, Quan-Yang Duh, Hormoz Ehya, Megan Haymart, Carl Hoh, Jason P. Hunt, Andrei Iagaru, Fouad Kandeel, Peter Kopp, Dominick M. Lamonica, Judith C. McCaffrey, Jeffrey F. Moley, Lee Parks, Christopher D. Raeburn, John A. Ridge, Matthew D. Ringel, Randall P. Scheri, Jatin P. Shah, Robert C. Smallridge, Cord Sturgeon, Thomas N. Wang, Lori J. Wirth, Karin G. Hoffmann, and Miranda Hughes

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Thyroid Carcinoma focuses on anaplastic carcinoma because substantial changes were made to the systemic therapy recommendations for the 2015 update. Dosages and frequency of administration are now provided, docetaxel/doxorubicin regimens were added, and single-agent cisplatin was deleted because it is not recommended for patients with advanced or metastatic anaplastic thyroid cancer.